Loading...
The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab)
On November 18, 2011, the US Food and Drug Administration (US FDA) announced that breast cancer indication for Avastin (bevacizumab) had been withdrawn after concluding that the drug has not been shown to be safe and effective for the treatment of breast cancer. The specific indication that was with...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2011
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3744967/ https://ncbi.nlm.nih.gov/pubmed/23960813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jsps.2011.12.001 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|